Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors: SEATTLE, April 12, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the first patient has been [...]
Respondology Secures $11 Million Funding
Respondology Secures $11 Million Funding Boulder, Colo. — April 13, 2023 —Respondology, a Boulder Heavy Industries portfolio company (BHI) co-founded by digital veterans to eradicate hate, abuse and spam on social media and to empower brands and organizations to optimally manage social engagement across multiple platforms, has announced the closure [...]
Kineta Completes Reverse Merger with Yumanity Therapeutics
Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse [...]
Recon Capital Team Joins Horizons ETFs Management (USA) LLC
BUSINESS WIRE Recon Capital Advisors, LLC (“RCA”), the investment adviser to the four exchange-traded funds that make up the Recon Capital Series Trust, has entered into an agreement to be acquired by Horizons ETFs Management (USA) LLC (“Horizons USA”), a member of the Horizons Exchange Traded Funds Group, one of [...]
Crunch Franchise Announces Its Newest Location In Huntingdon Valley, PA
PR Newswire NEW YORK, Nov. 1, 2016 NEW YORK, Nov. 1, 2016 /PRNewswire/ -- Crunch, the health club chain best known for making serious fitness fun through unique programming and cutting-edge training, announces the opening of its newest franchise location at 759 Huntingdon Pike, Huntingdon Valley, PA. The club opened [...]
Seattle biotech firm Kineta raises $1.6 million to boost its battle against disease
Kineta, a Seattle-based biotech startup, has raised an investment round worth almost $1.6 million from existing investors in the company. The investment will be used to fund continued development of the drugs that the company is working on. “This new raise comes from existing investors and shows confidence in what the [...]
Kineta, Inc. and RLB Holdings Announce New Joint Venture to Address High-Need Therapeutics Including Autoimmune Diseases
Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs. “The [...]
Kineta, Children’s join in pediatric clinical-trial effort
Seattle biotechnology company Kineta and Seattle Children’s Research Institute are joining in an effort to improve development and testing of therapies for pediatric autoimmune diseases. Their collaboration, called Alliance for Children’s Therapeutics, will be funded both by philanthropic gifts to the research institute and equity investments in Kineta. Its initial [...]